Harvard Scientists Develop 97% Accurate Fetal DNA Test From 1 Maternal Blood Sample
Updated
Updated · Inside Precision Medicine · Jun 12
Harvard Scientists Develop 97% Accurate Fetal DNA Test From 1 Maternal Blood Sample
3 articles · Updated · Inside Precision Medicine · Jun 12
Summary
565 pregnancies showed Harvard’s non-invasive fetal sequencing could identify 97.2% of reportable fetal variants normally found through invasive prenatal genome testing.
860x average sequencing coverage and ensemble machine learning let the test analyze the full exome from maternal blood, extending screening far beyond standard non-invasive tests focused mainly on chromosome-count disorders such as Down syndrome.
388 matched invasive samples validated the approach, with median sensitivity of 94.0% and precision of 94.9%; detection topped 97% for de novo and paternal variants but was lower for inherited maternal variants at about 95%.
Researchers also flagged confounding cases including abnormal twin tissue and mothers with male-donor bone marrow transplants, while Michael Talkowski’s startup First Genomic Insights is developing the test for possible U.S. commercialization.
With insurers deeming it 'unproven,' can this breakthrough prenatal test truly replace risky procedures for the average family?
Can a test that finds thousands of genetic flaws avoid creating an epidemic of parental anxiety over uncertain results?
Revolutionizing Prenatal Care: The Promise and Challenges of Non-Invasive Fetal Sequencing (NIFS)
Overview
Noninvasive fetal sequencing (NIFS) is transforming prenatal diagnostics by offering expectant parents a safer and more comprehensive way to assess fetal genetic conditions. Unlike traditional invasive procedures, NIFS provides accurate information without associated risks, addressing the limitations of current non-invasive prenatal testing (NIPT). By delivering deeper insights and greater reliability, NIFS overcomes challenges in complex scenarios, such as twin pregnancies or cases with confounding maternal medical histories. This advancement marks a significant shift in prenatal care, enabling earlier and more confident understanding of fetal health while reducing the need for invasive testing.